Tony E. Godfrey

Tony E. Godfrey

Auto-generated profile, based on publicly available information

Tony E. Godfrey

Department of Surgery, University of Rochester Medical Center, Rochester, NY

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LSLaleh Shayesteh
Laleh Shayesteh
YLYiling Lu
Yiling Lu
WKWen-Lin Kuo
Wen-Lin Kuo
RBRussell Baldocchi
Russell Baldocchi
TGTony Godfrey
Tony Godfrey
JGJoe W. Gray
Joe W. Gray

1 January 2000 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FTFlora Tassone
Flora Tassone
RHRandi J. Hagerman
Randi J. Hagerman
ATAnnette K. Taylor
Annette K. Taylor
LGLouise W. Gane
Louise W. Gane
TGTony E. Godfrey
Tony E. Godfrey
PHPaul J. Hagerman
Paul J. Hagerman

24 March 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ADAustin M Dulak
Austin M Dulak
PSPetar Stojanov
Petar Stojanov
SPShouyong Peng
Shouyong Peng
MLMichael S Lawrence
Michael S Lawrence
CFCameron Fox
Cameron Fox
ABAdam J Bass
Adam J Bass
Adam Bass, Gad Getz and colleagues report whole-exome sequencing of 149 esophageal adenocarcinomas (EACs) and whole-genome sequencing of 15 EACs. They identify a mutational signature defined by a high prevalence of A>C transversions, as well as 26 genes mutated at high frequency in EACs. The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ∼15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.

1 February 2008 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AFAndrew Feber
Andrew Feber
LXLiqiang Xi
Liqiang Xi
JLJames D. Luketich
James D. Luketich
APArjun Pennathur
Arjun Pennathur
RLRodney J. Landreneau
Rodney J. Landreneau
VLVirginia R. Litle
Virginia R. Litle

1 May 2000 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
TGTony E. Godfrey
Tony E. Godfrey
SKSun-Hun Kim
Sun-Hun Kim
MCMarielena Chavira
Marielena Chavira
DRDavid W. Ruff
David W. Ruff
RWRobert S. Warren
Robert S. Warren
RJRonald H. Jensen
Ronald H. Jensen

21 July 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CCColin Collins
Colin Collins
JRJohanna M. Rommens
Johanna M. Rommens
DKDavid Kowbel
David Kowbel
TGTony Godfrey
Tony Godfrey
MTMinna Tanner
Minna Tanner
JGJoe W. Gray
Joe W. Gray
We report here the molecular cloning of an ≈1-Mb region of recurrent amplification at 20q13.2 in breast cancer and other tumors and the delineation of a 260-kb common region of amplification. Analysis of the 1-Mb region produced evidence for five genes, ZNF217 , ZNF218 , and NABC1 , PIC1L ( PIC1-l ike), CYP24 , and a pseudogene CRP ( C yclophillin R elated P seudogene). ZNF217 and NABC1 emerged as strong candidate oncogenes and were characterized in detail. NABC1 is predicted to encode a 585-aa protein of unknown function and is overexpressed in most but not all breast cancer cell lines in which it was amplified. ZNF217 is centrally located in the 260-kb common region of amplification, transcribed in multiple normal tissues, and overexpressed in all cell lines and tumors in which it is amplified and in two in which it is not. ZNF217 is predicted to encode alternately spliced, Kruppel-like transcription factors of 1,062 and 1,108 aa, each having a DNA-binding domain (eight C2H2 zinc fingers) and a proline-rich transcription activation domain.